ALX Oncology Holdings Inc.: Business Overview, Financials & Competitive Analysis
ALX Oncology Holdings Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). CD47 biomarker validation de-risks the approach, but clinical trial execution and competitive immuno-oncology landscape present significant execution challenges ahead. Recent clinical data shows biomarker-driven evidence that CD47 overexpression predicts evorpacept activity in HER2-positive gastric cancer with strong efficacy signals. However, as a pre-revenue clinical-stage company with modest cash.
What is ALX Oncology Holdings Inc.'s industry? ALX Oncology Holdings Inc. (alxoncology.com) operates in Biotechnology - Immuno-Oncology. AskCyborg classifies ALX Oncology Holdings Inc. under Biotechnology - Immuno-Oncology in its company registry.
ALX Oncology is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives. The company's lead therapeutic candidate, evorpacept, has demonstrate...
Cyborg Score thesis
CD47 biomarker validation de-risks the approach, but clinical trial execution and competitive immuno-oncology landscape present...
Read the full analyst-debate transcript →Get the Latest ALX Oncology Holdings Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeALX Oncology Holdings Inc. Overview
Pro stress-test →ALX Oncology is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives. The company's lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy and is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications.
Strategic Profile
Pro stress-test →The company targets cancer cells' use of CD47 as a "don't eat me" signal to evade immune detection, developing a next-generation checkpoint inhibitor designed to have high affinity for CD47 while avoiding hematologic toxicities of other CD47 blocking approaches. Evorpacept is in development as combination therapy with major pharmaceutical partners including Jazz Pharmaceuticals, Quantum Leap Healthcare, Sanofi, and academic institutions across multiple cancer types.
Competitive Landscape
Pro stress-test →ALX Oncology's competitive position centers on CD47 checkpoint pathway blocking with focus on bridging innate and adaptive immune systems. The immuno-oncology landscape includes players like Gilead/Forty Seven (also CD47-focused), Syndax (CD47 programs), and broader checkpoint inhibitor competitors, but ALX's biomarker-driven approach and Fc optimization differentiate its candidate.
Industry Context
ALX Oncology Holdings Inc. operates in Biotechnology - Immuno-Oncology.
Key facts
Headquarters: South San Francisco, California · Employees: 44 · Market cap: $80.8M